HIGHLIGHTS
- who: Ronen Stoff and collaborators from the The State University of New Jersey, United States have published the paper: Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients, in the Journal: (JOURNAL)
- what: To our knowledge this is the largest reported series of elderly patients treated with combination immunotherapy, and we believe it carries a significant impact.
- how: The combination of Nivolumab and Ipilimumab was tested in the pivotal Checkmate 067 trial and has given the best results to date with an improved response rate of 58% and a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.